| US 7,601,814 B2 | ||
| Reducing the immunogenicity of fusion proteins | ||
| Stephen D. Gillies, Carlisle, Mass. (US); Jeffrey Way, Cambridge, Mass. (US); and Anita A. Hamilton, Aberdeen (United Kingdom) | ||
| Assigned to Merck Patent GmbH, Darmstadt (Germany) | ||
| Filed on Sep. 23, 2005, as Appl. No. 11/233,683. | ||
| Application 11/233683 is a division of application No. 10/112582, filed on Mar. 29, 2002, granted, now 6,992,174. | ||
| Claims priority of provisional application 60/280625, filed on Mar. 30, 2001. | ||
| Prior Publication US 2006/0025573 A1, Feb. 02, 2006 | ||
| Int. Cl. C12P 21/08 (2006.01) | ||
| U.S. Cl. 530—387.3 [424/134.1; 424/178.1; 424/185.1; 424/192.1; 530/350; 530/388.1] | 7 Claims |
| 1. A fusion protein with reduced immunogenicity comprising:
a non-immunoglobulin protein and
an immunoglobulin protein fused to said non-immunoglobulin protein via a fusion junction,
wherein the amino acid sequence of a junction region surrounding the fusion junction is modified by substitution or deletion
of one or more amino acids to remove a non-self T-cell epitope,
wherein the junction region comprises an IgG region wherein the LSLS amino acid sequence (amino acids 3-6 of SEQ ID NO:5)
is mutated.
|